Latest news
Royalty Pharma Acquires Royalty Interest in Cliramitug from Neurimmune - Global Legal ChronicleGlobal Legal Chronicle · Mon, 10 Aug 2026 00:00:00 GMTRoyalty Pharma plc 2026: Revenue $674.14M, EPS $0.04— 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 13:11:01 GMTRoyalty Pharma reports Q2 2026: Portfolio Receipts $773M, Royalty Receipts up 14% - TradingViewTradingView · Wed, 05 Aug 2026 11:43:03 GMT